



PRESS RELEASE

Collectis to Present Data on Genome Engineering for Adoptive Immunotherapy at the American Society of Clinical Oncology Annual Meeting

New York, May 13, 2015 – Collectis S.A. (Alternext: ALCLS – Nasdaq Global Market: CLLS), a pioneering gene-editing company employing proprietary technologies to develop best-in-class products in the emerging field of immuno-oncology, today announced that preclinical data on its gene-edited allogeneic CAR T-cells will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will be held from May 29 to June 2, 2015 in Chicago, IL.

The presentations include:

- **UCART19, an Allogeneic “Off-the-Shelf” Adoptive T-Cell Immunotherapy Against CD19+ B-Cell Leukemias**
Poster Session: Developmental Therapeutics—Immunotherapy
Presentation Time: Saturday, May 30, 2015, 8:00 - 11:30 a.m. Central
- **Adoptive immunotherapy of acute myeloid leukemia (AML) with allogeneic CAR T-cells targeting CD123.**
Poster Session: Developmental Therapeutics—Immunotherapy
Presentation Time: Saturday, May 30, 2015, 8:00 - 11:30 a.m. Central
- **A multidrug resistant engineered CAR T-cell for allogeneic combination immunotherapy.**
Poster Session: Leukemia, Myelodysplasia, and Transplantation
Presentation Time: Sunday, May 31, 2015, 8:00 - 11:30 a.m. Central

About Collectis

Collectis is a gene-editing company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company’s mission is to develop a new generation of cancer therapies based on engineered T-cells. Collectis capitalizes on its 15 years of expertise in genome engineering - based on its flagship TALEN™ products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Collectis’ goal is to create innovative products in multiple fields and with various target markets. Collectis S.A. is listed on the Nasdaq Global Market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.collectis.com

For further information, please contact:

Media contact

Jennifer Moore, Director of Communications
Phone: +1 917 580-1088
email: media@collectis.com

BMC Communications

Brad Miles

Phone: 646-513-3125

email: bmiles@bmccommunications.com

IR contacts

Simon Harnest, VP Finance and Investor Relations

Phone: 646-385-9008

email: simon.harnest@collectis.com